CME/CE - Global Oncology Academy

Episodes 113-123 of 123

Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
MinuteCE®
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
MinuteCE®
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
MinuteCE®
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
MinuteCE®
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
1.25 program credits
- Yelena Janjigian, MD
1.25 program credits
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
MinuteCE®
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
MinuteCE®
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
1.25 credits 11 episodes
- Yelena Janjigian, MD
- Samuel J. Klempner, MD
1.25 credits 11 episodes
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
CME/CE
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
0.25 credits
- Jonathan D. Schoenfeld, MD, MPhil, MPH
- Robert L. Ferris, MD, PhD
0.25 credits
Accelerating Evidence-Based Care in LA SCCHN
Accelerating Evidence-Based Care in LA SCCHN
CME/CE
Accelerating Evidence-Based Care in LA SCCHN
0.25 credits
- Ezra Cohen, MD, FRCPSC, FASCO
- Sue S. Yom, MD, PhD
0.25 credits
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
CME/CE
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
- Robert L. Coleman, MD, FACOG, FACS
- Susana Campos, MD, MPH
- Domenica Lorusso, MD, PhD
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CE
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
- Benjamin Levy, MD
- Rebecca Heist, MD, MPH
- Peter Bela Illei, MD

Previous
1
2
…
6
7
8
Next

8/6